Related Experiment Video

Updated: Jul 2, 2026

Simple Establishment of a Vascularized Osteogenic Bone Marrow Niche Using Pre-Cast Poly(ethylene Glycol) (PEG) Hydrogels in an Imaging Microplate
10:32

Simple Establishment of a Vascularized Osteogenic Bone Marrow Niche Using Pre-Cast Poly(ethylene Glycol) (PEG) Hydrogels in an Imaging Microplate

Published on: May 19, 2023

Angiostatic activity of obtustatin as alpha1beta1 integrin inhibitor in experimental melanoma growth

Meghan C Brown1, Izabela Staniszewska, Luis Del Valle

  • 1Department of Neuroscience, Center for Neurovirology and Cancer Biology, Temple University, School of Medicine, Philadelphia, PA, USA.

International Journal of Cancer
|August 21, 2008
PubMed

Insights

Obtustatin, a snake venom peptide, effectively inhibits melanoma growth by targeting alpha1beta1 integrin and blocking tumor angiogenesis. This compound shows therapeutic potential for vascularized melanoma treatment.

Area of Science:

  • Integrin signaling in cancer biology
  • Tumor angiogenesis and metastasis
  • Peptide-based therapeutics

Background:

  • Alpha1beta1 integrin is a collagen receptor on endothelial cells, crucial for tumor angiogenesis.
  • Melanoma, particularly highly vascularized types, presents therapeutic challenges.
  • Disintegrins are peptides known to inhibit integrin function.

Purpose of the Study:

  • To investigate the therapeutic effect of obtustatin, a disintegrin, on experimental melanoma.
  • To determine if obtustatin's efficacy is linked to the inhibition of angiogenesis.
  • To elucidate the mechanism of action of obtustatin in melanoma progression.

Main Methods:

  • Administration of obtustatin, a snake venom KTS-disintegrin, as an alpha1beta1 integrin inhibitor.
  • Testing in two animal models: quail chorioallantoic membrane (CAM) assay and mouse models (nude mice with MV3 melanoma, syngeneic B16F10 melanoma model).
  • Assessment of tumor growth, neovascularization, endothelial cell proliferation, and apoptosis.

Main Results:

  • Obtustatin demonstrated potent oncostatic effects on melanoma progression in both quail and mouse models.
  • Therapeutic efficacy correlated with significant inhibition of pathological angiogenesis and neovascularization.
  • Obtustatin blocked microvascular endothelial cell proliferation, inducing caspase-dependent apoptosis.

Conclusions:

  • Obtustatin is a promising low-molecular-weight therapeutic agent for melanoma treatment.
  • Its mechanism involves targeting alpha1beta1 integrin, inhibiting angiogenesis, and inducing endothelial cell apoptosis.
  • Obtustatin shows particular potential for treating highly vascularized melanomas.

Related Concept Videos

Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Integrins01:10

Integrins

Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...